AML1-Evi-1 specifically transforms hematopoietic stem cells through fusion of the entire Evi-1 sequence to AML1

被引:13
作者
Takeshita, M.
Ichikawa, M.
Nitta, E.
Goyama, S.
Asai, T.
Ogawa, S.
Chiba, S. [2 ]
Kurokawa, M. [1 ]
机构
[1] Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Bunkyo Ku, Tokyo 1138655, Japan
[2] Univ Tokyo, Grad Sch Med, Dept Cell Therapy & Transplantat Med, Tokyo 1138655, Japan
关键词
RUNX1; AML1; Evi-1; leukemogenesis;
D O I
10.1038/leu.2008.53
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The t(3; 21) chromosomal translocation seen in blastic crisis of chronic myeloid leukemia and secondary leukemias results in a formation of a chimeric protein AML1-Evi-1, which suppresses wild-type AML1 function. Loss of AML1 function causes expansion of hematopoietic progenitor cells, whereas it is not sufficient for the development of leukemia. To identify essential mechanisms through which AML1-Evi-1 exerts full leukemogenic potential, we introduced AML1-Evi-1 and its mutants in murine bone marrow cells, and evaluated their transforming activities by colony replating assays. The transforming activity of AML1-Evi-1 was lost when any of the known functional domains of Evi-1 was deleted from the chimeric protein, and forced expression of Evi-1 did not transform the AML1-deleted bone marrow cells. Unlike the MLL-ENL and AML1-ETO leukemia-related chimeric proteins, AML1- Evi-1 could transform only the hematopoietic stem cell fraction. Moreover, AML1-Evi-1-transformed cells show a cell-marker profile distinct from that of the cells transformed by AML1-ETO, which also suppresses AML1 function. Thus, leukemogenic activity of AML1-Evi-1 may be due to activation of molecular mechanisms distinct from those activated by MLL-ENL or AML1-ETO in the hematopoietic stem cell fractions.
引用
收藏
页码:1241 / 1249
页数:9
相关论文
共 32 条
[1]   Interaction of EVI1 with cAMP-responsive element-binding protein-binding protein (CBP) and p300/CBP-associated factor (P/CAF) results in reversible acetylation of EVI1 and in co-localization in nuclear speckles [J].
Chakraborty, S ;
Senyuk, V ;
Sitailo, S ;
Chi, YQ ;
Nucifora, G .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (48) :44936-44943
[2]   Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors [J].
Cozzio, A ;
Passegué, E ;
Ayton, PM ;
Karsunky, H ;
Cleary, ML ;
Weissman, IL .
GENES & DEVELOPMENT, 2003, 17 (24) :3029-3035
[3]   Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice [J].
Cuenco, GM ;
Ren, RB .
ONCOGENE, 2004, 23 (02) :569-579
[4]   Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: A model for human AML [J].
Cuenco, GM ;
Nucifora, G ;
Ren, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (04) :1760-1765
[5]   MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP [J].
Deguchi, K ;
Ayton, PM ;
Carapeti, M ;
Kutok, JL ;
Snyder, CS ;
Williams, IR ;
Cross, NCP ;
Glass, CK ;
Cleary, ML ;
Gilliland, DG .
CANCER CELL, 2003, 3 (03) :259-271
[6]  
ERICKSON P, 1992, BLOOD, V80, P1825
[7]   Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype [J].
Growney, JD ;
Shigematsu, H ;
Li, Z ;
Lee, BH ;
Adeisperger, J ;
Rowan, R ;
Curley, DP ;
Kutok, JL ;
Akashi, K ;
Williams, IR ;
Speck, NA ;
Gilliland, DG .
BLOOD, 2005, 106 (02) :494-504
[8]   Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia [J].
Higuchi, M ;
O'Brien, D ;
Kumaravelu, P ;
Lenny, N ;
Yeoh, EJ ;
Downing, JR .
CANCER CELL, 2002, 1 (01) :63-74
[9]   MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors [J].
Huntly, BJP ;
Shigematsu, H ;
Deguchi, K ;
Lee, BH ;
Mizuno, S ;
Duclos, N ;
Rowan, R ;
Amaral, S ;
Curley, D ;
Williams, IR ;
Akashi, K ;
Gilliland, DG .
CANCER CELL, 2004, 6 (06) :587-596
[10]   AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis [J].
Ichikawa, M ;
Asai, T ;
Saito, T ;
Yamamoto, G ;
Seo, S ;
Yamazaki, I ;
Yamagata, T ;
Mitani, K ;
Chiba, S ;
Hirai, H ;
Ogawa, S ;
Kurokawa, M .
NATURE MEDICINE, 2004, 10 (03) :299-304